Merck & Company (MRK) 59.50 $MRK
Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:23AM CDT
Gilead Sciences' (GILD) first pan-genotypic, single-tablet regimen, Epclusa, gained EU approval for the treatment of all genotypes of chronic hepatitis C.
INVA: 11.91 (+0.15), FCSC: 1.17 (-0.02), GILD: 86.29 (-0.34), MRK: 59.50 (-0.10)
Mylan Launches Generic Temodar® Capsules
PR Newswire - Mon Jul 11, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Temozolomide Capsules are indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
MRK: 59.50 (-0.10), MYL: 45.41 (+0.25)
Merck's Healthcare Services & Solutions Invests in Majority Stake in StayWell
BusinessWire - Mon Jul 11, 6:00AM CDT
The StayWell Company LLC ("StayWell" or "the Company"
, a portfolio company of Vestar Capital Partners ("Vestar", today announced that Healthcare Services & Solutions, LLC ("HSS", a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. ("Merck", has invested in a majority stake in the Company.
MRK: 59.50 (-0.10)
Dow 30 Stock Roundup: Chevron, Exxon Mobil to Invest in Kazakh Oil Field, Disney to Buy Stake in MLB Advanced Media
Swarup Gupta - Zacks Investment Research - Fri Jul 08, 10:05AM CDT
The Dow inched marginally upward during a holiday shortened week.
MON: 101.61 (-0.72), JPM: 62.98 (-0.22), IBM: 157.91 (+0.87), MRK: 59.50 (-0.10), XOM: 94.40 (-0.55), DIS: 100.00 (-0.20), CVX: 106.15 (-0.63), MSFT: 53.67 (+0.46), CSCO: 29.75 (+0.14)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 61.80 (-0.35), BIIB: 251.59 (-1.77), VRTX: 88.52 (-1.11), GILD: 86.29 (-0.34), UNH: 140.80 (+0.94), MRK: 59.50 (-0.10), ALXN: 123.57 (-1.78), XOM: 94.40 (-0.55), CVX: 106.15 (-0.63), REGN: 365.72 (-3.03), CELG: 102.64 (-0.77)
CSI Laboratories Launches PD-L1 Expression Assay That Can Be Used in Conjunction with Multiple Immunotherapies
BusinessWire - Thu Jul 07, 7:30AM CDT
CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay that can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies.(1)
MRK: 59.50 (-0.10), BMY: 76.49 (+0.29)
Merck Rises 1.45% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 06, 11:59AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.07 to a high of $58.85. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $58.17 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 59.50 (-0.10)
Merck Set to Possibly Pullback After Yesterday's Rally of 1.45%
Comtex SmarTrend(R) - Wed Jul 06, 11:58AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.07 to a high of $58.85. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $58.17 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 59.50 (-0.10)
Merck to Acquire Brazilian Animal Health Company for $400M
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:28AM CDT
Merck (MRK) announced that it will acquire the controlling interest in Vallee S.A., a Brazil-based privately held producer of animal health products.
GWPH: 92.42 (-4.68), ANIP: 54.51 (-1.22), UTHR: 109.46 (-3.47), MRK: 59.50 (-0.10)
Orange Business Services Helps Merck Achieve Its Digital Transformation Objectives with New Network and Services
BusinessWire - Tue Jul 05, 8:00AM CDT
--Data and applications accelerated by WAN optimization with Riverbed
MRK: 59.50 (-0.10), ORAN: 15.97 (-0.07)
Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallee S.A.
BusinessWire - Fri Jul 01, 11:05AM CDT
Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has executed an agreement to acquire a controlling interest in Vallee S.A., a leading privately-held producer of animal health products in Brazil.
MRK: 59.50 (-0.10)
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
CNW Group - Fri Jul 01, 4:30AM CDT
Not intended for UK- or US-based media
MRK: 59.50 (-0.10)
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:50AM CDT
Lilly (LLY) and its partner, Boehringer, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular risk reduction.
JNJ: 122.88 (-0.04), NVO: 55.45 (-0.10), MRK: 59.50 (-0.10), LLY: 79.53 (-0.14)
Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients
BusinessWire - Thu Jun 30, 7:31AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis patients.
MRK: 59.50 (-0.10), PINC: 34.06 (+0.04)
Research Report Initiated on Select Major Drug Manufacturers Equities
ACCESSWIRE - Wed Jun 29, 8:18AM CDT
LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Major industry. Companies recently under review include Pfizer, Merck, AbbVie, and Johnson & Johnson. See our complete report on Pfizer at:
JNJ: 122.88 (-0.04), MRK: 59.50 (-0.10), PFE: 36.26 (+0.02), ABBV: 64.65 (-0.85)
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA(R) (pembrolizumab) for the Treatment of Multiple Types of Cancer
BusinessWire - Wed Jun 29, 6:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck's established leadership in immuno-oncology with Moderna's pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers.
MRK: 59.50 (-0.10)
Frost & Sullivan Applauds Merck for Staying Ahead of the Changing Colour and Texture Trends in the Automotive OEM Pigments Market with its Meoxal® and Xirallic® NXT Lines
PR Newswire - Wed Jun 29, 5:06AM CDT
Based on its recent analysis of the automotive original equipment manufacturer (OEM) pigments market, Frost & Sullivan recognizes Merck with the 2016 European Frost & Sullivan Award for Product Leadership. Merck's Meoxal® and Xirallic® NXT lines are redefining trends in the automotive pigments market by creating new colours and textures for automotive OEMs. Its strict adherence to regulatory standards and global manufacturing guidelines has resulted in the best-performing automotive pigments in the market.
MRK: 59.50 (-0.10)
FDA approves first pill to treat all forms of hepatitis C
By MATTHEW PERRONE - AP - Tue Jun 28, 3:19PM CDT
WASHINGTON (AP) — Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
GILD: 86.29 (-0.34), MRK: 59.50 (-0.10), BMY: 76.49 (+0.29)
Merck to Develop Next-Generation Purification Processes with International Vaccine Institute
PR Newswire Europe - Tue Jun 28, 7:01AM CDT
- Company to provide expertise on clarification and purification
MRK: 59.50 (-0.10)
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
BusinessWire - Mon Jun 27, 5:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA(R) (pembrolizumab), the company's anti-PD-1 therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. The CHMP positive opinion for KEYTRUDA will now be reviewed by the European Commission for marketing authorization in the European Union (EU).
MRK: 59.50 (-0.10)
Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:23AM CDT
Gilead Sciences' (GILD) first pan-genotypic, single-tablet regimen, Epclusa, gained EU approval for the treatment of all genotypes of chronic hepatitis C.
INVA: 11.91 (+0.15), FCSC: 1.17 (-0.02), GILD: 86.29 (-0.34), MRK: 59.50 (-0.10)
Mylan Launches Generic Temodar® Capsules
PR Newswire - Mon Jul 11, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Temozolomide Capsules are indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
MRK: 59.50 (-0.10), MYL: 45.41 (+0.25)
Merck's Healthcare Services & Solutions Invests in Majority Stake in StayWell
BusinessWire - Mon Jul 11, 6:00AM CDT
The StayWell Company LLC ("StayWell" or "the Company"
, a portfolio company of Vestar Capital Partners ("Vestar", today announced that Healthcare Services & Solutions, LLC ("HSS", a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. ("Merck", has invested in a majority stake in the Company. MRK: 59.50 (-0.10)
Dow 30 Stock Roundup: Chevron, Exxon Mobil to Invest in Kazakh Oil Field, Disney to Buy Stake in MLB Advanced Media
Swarup Gupta - Zacks Investment Research - Fri Jul 08, 10:05AM CDT
The Dow inched marginally upward during a holiday shortened week.
MON: 101.61 (-0.72), JPM: 62.98 (-0.22), IBM: 157.91 (+0.87), MRK: 59.50 (-0.10), XOM: 94.40 (-0.55), DIS: 100.00 (-0.20), CVX: 106.15 (-0.63), MSFT: 53.67 (+0.46), CSCO: 29.75 (+0.14)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 61.80 (-0.35), BIIB: 251.59 (-1.77), VRTX: 88.52 (-1.11), GILD: 86.29 (-0.34), UNH: 140.80 (+0.94), MRK: 59.50 (-0.10), ALXN: 123.57 (-1.78), XOM: 94.40 (-0.55), CVX: 106.15 (-0.63), REGN: 365.72 (-3.03), CELG: 102.64 (-0.77)
CSI Laboratories Launches PD-L1 Expression Assay That Can Be Used in Conjunction with Multiple Immunotherapies
BusinessWire - Thu Jul 07, 7:30AM CDT
CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay that can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies.(1)
MRK: 59.50 (-0.10), BMY: 76.49 (+0.29)
Merck Rises 1.45% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 06, 11:59AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.07 to a high of $58.85. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $58.17 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 59.50 (-0.10)
Merck Set to Possibly Pullback After Yesterday's Rally of 1.45%
Comtex SmarTrend(R) - Wed Jul 06, 11:58AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.07 to a high of $58.85. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $58.17 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 59.50 (-0.10)
Merck to Acquire Brazilian Animal Health Company for $400M
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:28AM CDT
Merck (MRK) announced that it will acquire the controlling interest in Vallee S.A., a Brazil-based privately held producer of animal health products.
GWPH: 92.42 (-4.68), ANIP: 54.51 (-1.22), UTHR: 109.46 (-3.47), MRK: 59.50 (-0.10)
Orange Business Services Helps Merck Achieve Its Digital Transformation Objectives with New Network and Services
BusinessWire - Tue Jul 05, 8:00AM CDT
--Data and applications accelerated by WAN optimization with Riverbed
MRK: 59.50 (-0.10), ORAN: 15.97 (-0.07)
Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallee S.A.
BusinessWire - Fri Jul 01, 11:05AM CDT
Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has executed an agreement to acquire a controlling interest in Vallee S.A., a leading privately-held producer of animal health products in Brazil.
MRK: 59.50 (-0.10)
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
CNW Group - Fri Jul 01, 4:30AM CDT
Not intended for UK- or US-based media
MRK: 59.50 (-0.10)
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:50AM CDT
Lilly (LLY) and its partner, Boehringer, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular risk reduction.
JNJ: 122.88 (-0.04), NVO: 55.45 (-0.10), MRK: 59.50 (-0.10), LLY: 79.53 (-0.14)
Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients
BusinessWire - Thu Jun 30, 7:31AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis patients.
MRK: 59.50 (-0.10), PINC: 34.06 (+0.04)
Research Report Initiated on Select Major Drug Manufacturers Equities
ACCESSWIRE - Wed Jun 29, 8:18AM CDT
LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Major industry. Companies recently under review include Pfizer, Merck, AbbVie, and Johnson & Johnson. See our complete report on Pfizer at:
JNJ: 122.88 (-0.04), MRK: 59.50 (-0.10), PFE: 36.26 (+0.02), ABBV: 64.65 (-0.85)
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA(R) (pembrolizumab) for the Treatment of Multiple Types of Cancer
BusinessWire - Wed Jun 29, 6:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck's established leadership in immuno-oncology with Moderna's pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers.
MRK: 59.50 (-0.10)
Frost & Sullivan Applauds Merck for Staying Ahead of the Changing Colour and Texture Trends in the Automotive OEM Pigments Market with its Meoxal® and Xirallic® NXT Lines
PR Newswire - Wed Jun 29, 5:06AM CDT
Based on its recent analysis of the automotive original equipment manufacturer (OEM) pigments market, Frost & Sullivan recognizes Merck with the 2016 European Frost & Sullivan Award for Product Leadership. Merck's Meoxal® and Xirallic® NXT lines are redefining trends in the automotive pigments market by creating new colours and textures for automotive OEMs. Its strict adherence to regulatory standards and global manufacturing guidelines has resulted in the best-performing automotive pigments in the market.
MRK: 59.50 (-0.10)
FDA approves first pill to treat all forms of hepatitis C
By MATTHEW PERRONE - AP - Tue Jun 28, 3:19PM CDT
WASHINGTON (AP) — Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
GILD: 86.29 (-0.34), MRK: 59.50 (-0.10), BMY: 76.49 (+0.29)
Merck to Develop Next-Generation Purification Processes with International Vaccine Institute
PR Newswire Europe - Tue Jun 28, 7:01AM CDT
- Company to provide expertise on clarification and purification
MRK: 59.50 (-0.10)
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
BusinessWire - Mon Jun 27, 5:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA(R) (pembrolizumab), the company's anti-PD-1 therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. The CHMP positive opinion for KEYTRUDA will now be reviewed by the European Commission for marketing authorization in the European Union (EU).
MRK: 59.50 (-0.10)
